Genotropin Treatment In Very Young Children Born Small For Gestational Age

Phase 3 Completed 43 enrolled Pfizer

RandomizedParallel-groupOpen-labelTreatment

To demonstrate the effect on height and psychomotor development of Growth Hormone treatment in very young children starting at an age of 2 years.

Met primary endpoint

registry Genotropin® vs Control; p <0.001; Mean Difference (Final Values) 1.20 (95% CI 0.82 to 1.59); ANCOVA; NCT00627523 ↗

Evaluation	Drug	Modality	Dose	Route
Subject	Somatropin	Protein / enzyme biologic	0.035 mg/kg	Subcutaneous